Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia
- PMID: 15231874
- DOI: 10.1210/me.2004-0182
Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia
Abstract
We previously identified pituitary tumor-derived fibroblast growth factor receptor 4 (ptd-FGFR4), an alternatively transcribed N-terminally truncated cytoplasmic receptor isoform. Unlike wild-type FGFR4, ptd-FGFR4 facilitates cell transformation and results in pituitary tumor formation in transgenic mice. To investigate differences in the tumorigenic properties of FGFR4 and ptd-FGFR4, we examined their abilities to modulate cell adhesiveness. Introduction of ptd-FGFR4 into GH4 pituitary cells or NIH 3T3 fibroblasts resulted in significant reduction in cell adhesion to a collagen IV matrix compared with FGFR4- or empty vector-transfected cells. This adhesive difference was evident in the absence or presence of FGF stimulation. Furthermore, treatment with beta1-integrin neutralizing antibody markedly reduced adhesiveness in FGFR4-transfected cells but had little effect on the depressed adhesiveness of ptd-FGFR4-transfected cells. Unlike wild-type FGFR4, ptd-FGFR4 does not associate with neural cell-adhesion molecule (NCAM). Cells expressing FGFR4 demonstrate membranous N-cadherin with a noninvasive growth pattern identical to control GH4 cells when injected into immunodeficient mice. In contrast, ptd-FGFR4-expressing cells develop invasive tumors in vivo with marked loss of N-cadherin that localizes to the cytoplasm. Consistent with these changes, beta-catenin expression was diminished and its interaction with N-cadherin was disrupted in the presence of ptd-FGFR4, but both were intact in the presence of wild-type FGFR4. These data highlight the importance of membrane-anchored FGFR4 in assembling a multiprotein FGFR4 complex with NCAM and N-cadherin playing pivotal functions in maintaining normal cell adhesion. Disruption of distinct NCAM/N-cadherin proadhesive complexes by a tumor-derived FGFR4 isoform provides a novel mechanism beyond ligand independence that explains the pathobiology of proliferative and infiltrative but nonmetastatic neoplasms.
Similar articles
-
Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.Mol Endocrinol. 2006 Nov;20(11):2965-75. doi: 10.1210/me.2006-0223. Epub 2006 Jul 20. Mol Endocrinol. 2006. PMID: 16857743
-
Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness.J Clin Endocrinol Metab. 2004 Apr;89(4):1904-11. doi: 10.1210/jc.2003-031489. J Clin Endocrinol Metab. 2004. PMID: 15070963
-
Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.Clin Endocrinol (Oxf). 2008 Mar;68(3):435-41. doi: 10.1111/j.1365-2265.2007.03062.x. Epub 2007 Dec 7. Clin Endocrinol (Oxf). 2008. PMID: 18070145
-
The molecular pathogenetic role of cell adhesion in endocrine neoplasia.J Clin Pathol. 2005 Nov;58(11):1121-5. doi: 10.1136/jcp.2004.024521. J Clin Pathol. 2005. PMID: 16254096 Free PMC article. Review.
-
N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling.Int J Dev Biol. 2004;48(5-6):463-76. doi: 10.1387/ijdb.041793ld. Int J Dev Biol. 2004. PMID: 15349821 Review.
Cited by
-
Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.Am J Pathol. 2010 Dec;177(6):2860-9. doi: 10.2353/ajpath.2010.100509. Epub 2010 Oct 29. Am J Pathol. 2010. Retraction in: Am J Pathol. 2015 Aug;185(8):2339. doi: 10.1016/j.ajpath.2015.04.025. PMID: 21037081 Free PMC article. Retracted.
-
Management of aggressive pituitary adenomas and pituitary carcinomas.J Neurooncol. 2014 May;117(3):459-68. doi: 10.1007/s11060-014-1413-6. Epub 2014 Mar 2. J Neurooncol. 2014. PMID: 24584748 Review.
-
The role of MMP-1 and FGFR4-R388 gene polymorphisms in pituitary adenoma.Acta Med Litu. 2017;24(4):177-190. doi: 10.6001/actamedica.v24i4.3613. Acta Med Litu. 2017. PMID: 29487481 Free PMC article.
-
Prognostic factors of regrowth in nonfunctioning pituitary tumors.Pituitary. 2018 Apr;21(2):176-182. doi: 10.1007/s11102-017-0861-3. Pituitary. 2018. PMID: 29288467 Review.
-
Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Literature Review.Cancers (Basel). 2019 Dec 4;11(12):1936. doi: 10.3390/cancers11121936. Cancers (Basel). 2019. PMID: 31817110 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous